Follow Us On

Facebook  X  Linkedin  YouTube
 
 
 

All Medicare Administrative Contractors (MACs), including CGS, NGS, Noridian, Palmetto, and WPS, except Novitas and First Coast Service Options, have released new Local Coverage Determinations (LCDs) for peripheral nerve blocks and procedures for chronic pain.


The new LCDs provide coverage only for radiofrequency neurolysis for trigeminal neuralgia, corticosteroid injections for median neuropathy at the wrist (limited to a maximum of three injections), and corticosteroid injections for Morton’s neuroma (limited to a maximum of two injections).


All other peripheral nerve block and related procedures are not covered under these policies.

  1. Occipital nerve block and denervation
  2. Stellate ganglion block
  3. Trigeminal nerve block
  4. Suprascapular nerve block
  5. Thoracic nerve block
  6. Thoracic nerve denervation
  7. Genicular nerve blocks (GNB), cryoneurolysis or ablation
  8. Pudendal nerve block
  9. Digital nerve block
  10. Posterior tibial nerve block at the tarsal tunnel
  11. Ulnar nerve block
  12. Denervation of the trigeminal nerve for any diagnosis other than TN
  13. Any other peripheral nerves blocks, or denervation not listed above


This policy eliminates all procedures except for facet joint interventions and epidural interventions.


As practitioners, we recognize the clinical importance of these procedures. However, they are not performed very frequently, making it surprising that such a restrictive policy has been proposed—one that effectively removes nearly all other interventional options.


ASIPP will be submitting a formal comment letter and is urging all state societies to do the same.


Public comments are open until November 8 for CGS, NGS, Noridian, and Palmetto, and until November 22 for WPS.


Comments may be submitted directly through each Medicare Administrative Contractor (MAC) by using the links provided below:

Open Comment Period: Closes Nov. 8.

Open Comment Period: Closes Nov. 8.

Open Comment Period: Closes Nov. 8.

Open Comment Period:

Closes Nov. 8.

Open Comment Period:

Closes Nov. 22.

We will stay in touch and provide you with a copy of the ASIPP letter. You will receive ASIPP’s official comment letter, which you can use as a reference to develop your own. However, if you would like to submit your letter before then, please feel free to do so.


When preparing your letter, please follow the principles below:

  • Be respectful.
  • Identify yourself and your practice.
  • Clearly express your concerns.
  • Offer solutions, if applicable. Possible recommendations include:
  1. Withdraw the LCD entirely.
  2. Modify coverage policies to allow two diagnostic blocks followed by two radiofrequency neurotomy procedures per year, if applicable, or four therapeutic nerve blocks.
  3. The treatment should be performed only if patients experience at least 50% improvement following both the first and second diagnostic blocks.
  • Conclude your letter by thanking the MAC for their consideration.
  • Keep in mind that the LCD itself includes detailed background information for each procedure.
  • You may also reference supporting literature, either external sources or citations included within the LCD.


Click here to comment.

Stay up-to-date with news that impacts you - visit our website or follow us on these social media platforms:

Facebook  LinkedIn  X  YouTube

Register now for this ASIPP webinar!

Don’t miss the opportunity to engage with leading experts on October 21, 2025 as we explore how AI is transforming electronic health records and prescribing practices. This webinar is the first in a six-part series: the Modernizing Your Practice Through Medical Technology.


Each session focuses on a timely topic shaping the future of patient care—from electronic health records and AI prescribing to emerging tools that enhance efficiency, accuracy, and outcomes. Stay engaged each month and gain insights you can put into practice right away.


Topics include:

  • Introduction by Laxmaiah Manchikanti, MD
  • AI Scribing featuring PlayBackHealth.com
  • AI Prescribing featuring SureMedCompliance.com
  • Q&As
  • Moderator discussions

aAlzheimer's Blood Test Cleared for Primary Care Use

Elecsys pTau181 test can help rule out Alzheimer's-related amyloid pathology



FDA cleared the Elecsys pTau181 test as the first blood-based biomarker to aid in the initial assessment of Alzheimer's disease and other causes of cognitive decline that can be used in the primary care setting, Roche announced on Monday.


The test measures plasma levels of phosphorylated tau 181 (p-tau181), one of the key markers of amyloid plaque and tau aggregate pathology behind Alzheimer's disease, and is intended for patients 55 and older who present with signs, symptoms, or complaints of cognitive decline to rule out Alzheimer's-related amyloid pathology in conjunction with other clinical information.


"By enabling use in primary care, the Elecsys pTau181 test has the potential to significantly broaden patient access to minimally invasive testing and helps preserve specialist resources," Roche said in a statement. "Primary care clinicians can better guide appropriate referrals so neurologists can focus on the patients most likely to need advanced evaluation and treatment."


Click here to read the full article.

A 35-year bibliometric analysis of global trends in randomized controlled trials for chronic pain therapy (1989-2024) highlights Laxmaiah Manchikanti, MD, as a prominent author with the highest publication counts, while Pain Physician ranks as the third highest ranked journal.


The study, conducted by Yang et al., analyzed 4,206 publications from 939 journals, authored by 20,068 individuals across 86 countries. The most cited article was “Clinical Importance of Changes in Chronic Pain Intensity Measured on an 11-Point Numeric Pain Rating Scale” (Pain. 2001 Nov;94(2):149-158).


Most Published and Cited Authors:

  1. Laxmaiah Manchikanti, MD
  2. Andrew R. Moore, DSc
  3. Sheena Derry, MA
  4. Christopher Eccleston, PhD
  5. Philip J. Wiffen
  6. Tonya M. Palermo, PhD
  7. Timothy R. Deer, MD


Top cited high-impact journals include:

  • Pain
  • Cochrane Database of Systematic Reviews
  • Pain Physician


The tables below summarize:

  • Publication and citation profiles of high-impact authors
  • Bibliometric indicators of high-impact journals




Restless Legs a Parkinson’s Disease Risk Factor?



Restless legs syndrome (RLS) has been linked to an increased risk for Parkinson’s disease (PD), in new findings that suggest the association may go beyond the dopaminergic pathway.


In a retrospective study of nearly 20,000 people, 1.6% of those with RLS developed PD compared with 1.0% of those without RLS. Among patients with RLS, treatment with dopamine agonists (DAs) was associated with a lower risk of developing PD (0.5%) vs untreated individuals (2.1%), suggesting a potential protective effect.


“Based on these findings, it may be more reasonable to interpret RLS as a potential risk factor for PD rather than an early manifestation,” lead investigator Myeonghwan Bang, MD, of the Department of Physical Medicine and Rehabilitation at the National Health Insurance Service Ilsan Hospital in Goyang, South Korea, and colleagues from South Korea wrote.


Click here to read the full article.

CMS issued the proposed rule CMS-1832-P on July 16, 2025, titled Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program.

 

On September 11, 2025, ASIPP submitted a comment letter advocating for the following:

 

  1. Elimination of proposed efficiency adjustment, which is inappropriate, and efficiency is rather decreasing than increasing.
  2. Due to escalating costs, practice expense cuts applicable to independent physicians need to be addressed.
  3. Ambulatory Specialty Model (ASM) appears to be without any evidence and inappropriate, putting independent physicians at high risk for survival; consequently, this should be eliminated or conducted on a voluntary trial for five years.
  4. Telehealth services must be made permanent.

 

Here are ASIPP’s detailed comment letter, Chairman Comer’s recent letter to CMS and OMB, and 3 published articles addressing this issue:

 

Stay up-to-date with news that impacts you - visit our website or follow us on these social media platforms:

Facebook  LinkedIn  X  YouTube




Poor Sleep Tied to Accelerated Brain Aging





Poor sleep quality has been linked to accelerated brain aging, potentially driven by inflammation, new research showed.


Middle-aged and older adults with poor sleep were more likely to have brains that looked older than their chronological age.


“Our findings provide evidence that poor sleep may contribute to accelerated brain aging and point to inflammation as one of the underlying mechanisms,” said principal investigator Abigail Dove, PhD, postdoctoral researcher with the Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden, in a press release.


Click here to read the full article.

Upcoming ASIPP Webinars

Register today!

Join ASIPP on January 17, 2026, for an important webinar: Unveiling the Complexities of Controlled Substance Management in Interventional Pain Management (IPM).


Controlled substance management continues to present challenges for pain physicians, from evolving regulations and compliance requirements to balancing patient care with risk mitigation. This webinar will provide expert guidance to help you navigate these complexities and strengthen your practice.

Join ASIPP on January 31, 2026, for our webinar Strategies for Successful Practice Management. This program will focus on practical approaches to strengthen your practice through improved documentation, compliance strategies, and effective practice-building techniques.


Whether you are looking to optimize workflows, ensure regulatory readiness, or position your practice for long-term growth, this webinar will provide valuable insights to support your success.

Gabapentin Use Skyrockets Despite Risks,
CDC Analysis Shows

Anticonvulsant was America's fifth favorite prescribed drug in 2024

 

Key Takeaways


• Gabapentin became the fifth most prescribed U.S. medication in 2024, a CDC analysis showed.



• From 2010 to 2024, prescriptions jumped from 79.5 to 177.6 per 1,000 people.



• Prescribing increased most for older adults and women.

Gabapentin prescribing rose sharply in recent years, with the generic drug becoming the fifth most dispensed product in retail pharmacies in 2024, a CDC analysis showed.


From 2010 to 2024, prescriptions jumped from 79.5 to 177.6 per 1,000 people, according to Gery Guy Jr., PhD, of the CDC National Center for Injury Prevention and Control, and co-authors.


Click here to read the full article.

Join Us in New Orleans for ASIPP 2026

Earn CMEs, Expand Networks, and Explore the Future of Pain Management

It is our pleasure to invite you to the American Society of Interventional Pain Physicians’ 2026 Annual Meeting, where we will continue to shape the future of Interventional Pain Management.


This 28th Annual Meeting will take place Thursday, March 19 through Saturday, March 21, 2026, at the Hilton New Orleans Riverside in New Orleans, Louisiana.


The 2026 Annual Meeting will provide the tools, knowledge, and connections you need to thrive in the evolving field of interventional pain management.

JOIN or RENEW your ASIPP Membership for the best registration rates.



Initiating GLP-1 Drugs May Slightly Raise Depression Risk




Among patients with type 2 diabetes (T2D) and overweight or obesity, the initiation of GLP-1 receptor agonists (RAs) was associated with a 9% higher risk for incident depression than the initiation of SGLT2 inhibitors, with the association being stronger in older adults. The increased risk plateaued after 6 months and should be balanced against the mortality benefit associated with GLP-1 therapy.


METHODOLOGY:

  • GLP-1 RAs have raised ongoing concerns about neuropsychiatric harms, particularly depression and suicidality, with conflicting evidence leaving clinicians uncertain how to counsel patients.
  • To compare the risk for incident depression between GLP-1 RAs and SGLT2 inhibitors, researchers conducted a cohort study using deidentified electronic health records from healthcare organizations predominantly in the US from January 2016 to July 2024.
  • They identified 25,704 new GLP-1 RA users (mean age, 56.7 years; 48.6% men) matched 1:1 with 25,704 SGLT2 inhibitor users; all patients had newly diagnosed T2D and overweight or obesity, and those with prior mood disorders were excluded.


Click here to read the full article.

ASIPP continues working for YOU!

Our unwavering dedication to tackling the critical issues that matter most to our members creates a vibrant tapestry of community and collaboration among healthcare heroes. As we navigate the ever-changing currents of the healthcare landscape, we’re not just keeping our fingers on the pulse; we’re amplifying your voices to ensure that your needs are front and center! Together, we’re crafting a future where your concerns shape effective policies and practices. 


Here are a few recently published Pain Physician articles:

Health Policy Perspective - Pain Physician


Physician Payment Reform in Interventional Pain Management: Balancing Cost, Quality, Access, and Survival of Independent Practices


Laxmaiah Manchikanti, MD, Mahendra Sanapati, MD, Vidyasagar Pampati, MSc, Paul J. Hubbell, III, MD, Ann Conn, MD, Ramarao Pasupuleti, MD, Mayank Gupta, MD, Alan D. Kaye, MD, PhD, Alaa Abd-Elsayed, MD, Annu Navani, MD, Miles Day, MD, Devi Nampiaparampil, MD, Christopher G. Gharibo, MD, and Joshua A. Hirsch, MD


Abstract | PDF

 

Health Policy Perspective - Pain Physician


Escalating Growth of Spending on Medicare Advantage Plans: Save Medicare from Insolvency and Balance the Budget


Laxmaiah Manchikanti, MD, Mahendra Sanapati, MD, Paul J. Hubbell, III, MD, Ann Conn, MD, Mayank Gupta, MD, Ramarao Pasupuleti, MD, Alaa Abd-Elsayed, MD, and Alan D. Kaye, MD, PhD


Abstract | PDF

 

Health Policy Perspective - Pain Physician


Non-Partisan Proposal for Reforming Physician Payment System and Preserving Telehealth Services


Laxmaiah Manchikanti, MD, Paul J. Hubbell, III, MD, Ramarao Pasupuleti, MD, Ann Conn, MD, and Mahendra Sanapati, MD


Abstract | PDF

 

Health Policy Review - Pain Physician


BMJ Publications on Interventional Techniques Do Not Meet Appropriateness Criteria of Conducting a Rapid Review: A Comprehensive Review


Laxmaiah Manchikanti, MD, Mahendra Sanapati, MD, Amol Soin, MD, Alan D. Kaye, MD, PhD, Alaa Abd-Elsayed, MD, Christopher G. Gharibo, MD, Allen Dennis, MD, and Joshua A. Hirsch, MD


Abstract | PDF

Our Sponsor

Our Sponsor


Key Republican Senator Probes Major Source of AMA's Revenue

In a letter, Sen. Bill Cassidy asked the AMA how much it earns from licensing CPT codes



Senate health committee Chairman Bill Cassidy, MD (R-La.), blasted the American Medical Association (AMA) for continuing what he called a "government-backed monopoly" over Current Procedural Terminology (CPT) codes.


In an Oct. 6 letter, Cassidy pressed AMA President Bobby Mukkamala, MD, for an explanation of how CPT codes are generated, whose input is incorporated in developing them, and how much revenue the publication and licensing of these codes provides.


"I am particularly offended by the AMA abusing its government-endorsed CPT monopoly to charge every stakeholder in the health care system significant amounts of money while advancing an anti-patient agenda," Cassidy wrote.


Click here to read the full article.


Only three test dates left this year - Apply today!



October 25, November 15,

& December 13



  • ABIPP Part I

Four (4) hour virtual exam


  • ABIPP Path – Combined CCPM/ CSM Exam

For those with subspecialty in Pain Medicine

Two (2) hour virtual exam


  • ABIPP Competency Exam in IPM

For those without primary board certification

Two (2) hour virtual exam


  • ABIPP Competency Exam in Regenerative Medicine

Two (2) hour virtual exam


  • Controlled Substance Management Competency Exam

Two (2) hour virtual exam


  • Documentation, Coding, Compliance, Practice Management Competency Exam

Two (2) hour virtual exam

Exam Dates

Men Unlikely to Benefit Are Getting PSA Testing Anyhow

Study from across the pond reflects a common U.S. problem

 

Key Takeaways


• Routine PSA testing is not recommended by the USPSTF for men 70 and older, a group expected to derive little benefit.


• Similar to trends in the U.S., this U.K. study found that a high number of older men underwent PSA testing.


• PSA retesting also often occurred at shorter intervals than recommended in international guidelines

Prostate-specific antigen (PSA) testing for prostate cancer may be targeted to men unlikely to benefit from the test, including those age 70 and older, according to a U.K. study.


Contrary to recommendations regarding age and PSA screening, over the course of nearly two decades the highest PSA testing rates occurred in men 70 and above, a group considered least likely to benefit from repeat testing for prostate cancer, reported Kiana Collins, PhD, of the University of Oxford in England, and colleagues in The BMJ.


Click here to read the full article.

 

We're excited to let you know that the new ASIPP Community, hosted by DocMatter, is now live!


The ASIPP Community on DocMatter will serve as a place for members to collaborate around clinical and research topics to advance the care of their interventional pain patients.


Click here to be a part of the conversation!

Pain Medicine Case Reports (PMCR) and Editor-in-Chief Alaa Abd-Elsayed, MD, PhD would like to invite you to submit case reports and case series to the PMCR journal. Your article will be published free of charge.


Open access journals are freely available online for immediate worldwide open access to the full text of published articles. There is no subscription fee for open access journals. Open access journals are no different from traditional subscription-based journals: they undergo the same peer review and quality control as any other scholarly journal.


Interested in becoming a member of the PMCR Editorial Board?

Editorial board members are asked to review 2-6 manuscripts per year. Please submit your most up-to-date CV to sgold@asipp.org for consideration.


For more information or to submit your articles, click here.

We are excited to announce that Pain Medicine Case Reports (PMCR) journal (eISSN 2768-5152) has been accepted for inclusion in MEDLINE and PubMed, the prestigious bibliographic database of the U.S. National Library of Medicine. PMCR, a companion publication to the prestigious Pain Physician journal by ASIPP, joins its counterpart in achieving indexing in both MEDLINE and PubMed, marking ASIPP’s dual presence in these renowned databases.


The inclusion of PMCR journal in MEDLINE signifies a higher level of selectivity, as MEDLINE consists of the top 5,200 biomedical journals. This indexing also means that articles from PMCR will be searchable using NLM Medical Subject Headings (MeSH terms) and other metadata.


The selection for MEDLINE follows a rigorous evaluation process by reviewers from the Literature Selection Technical Review Committee (LSTRC). According to their criteria, the scientific quality of a journal’s content is the primary factor considered for indexing.


We extend our congratulations to the Pain Medicine Case Reports Editor-in-Chief, Deputy Editor-in-Chief, Journal Team, and Editorial Board for this achievement, which underscores the significance and excellence of this esteemed journal.

 

CASE REPORTS

An Unusual Challenging Case of Complex Regional Pain Syndrome Involving all 4 Limbs: A Case Report


Neha Singh, MD, and Emanuel N. Husu, MD

 

Isolated Musculocutaneous Nerve Palsy Following Supraclavicular Nerve Block: A Case Report


Daniel Ohlhausen, MD, Adam Benckendorf, DO, Derek Chung, DO, and Hamed Sadeghipour, MD

 

NEW ISSUE NOW AVAILABLE

 

OBSERVATIONAL STUDY

A Comparative Analysis of Single versus Double Intravertebral Reduction Device Implantation for Single-Level Osteoporotic Vertebral Fractures: Radiological and Clinical Outcomes


Yuan-Fu Liu, MD, Hao-Jun Chuang, MD, Yu-Chia Hsu, MD, Fu-Yao Fan, MD, Chao-Jui Chang, MD, and Cheng-Li Lin, MS

 

COHORT STUDY

HbA1c is Associated with Hyperglycemia After Local Dexamethasone Injection in Diabetes Mellitus Patients: A Cohort Study


Kumiko Tanabe, MD, PhD, Takuma Ishihara, PhD, Yoshimi Nakamura, MD, and Hiroki Iida, MD, PhD

 

CROSS-SECTIONAL SURVEY

Nonlinear Association Between Serum Lutein and Zeaxanthin Levels and Low Back Pain in US Adults: Results from the National Health and Nutrition Examination Survey


Shuai Qing, PhD, Shiming Huang, PhD, Jiang feng Wang, PhD, Min Xiao, PhD, and Qishan Yi, PhD




ASIPP is in collaboration with Curi Medical Liability Program




Since this malpractice insurance program officially launched in November 2018, ASIPP has signed up hundreds of providers with an average savings of 30%. This is professional liability insurance tailored to our specialty and will stand up for us and defend our practices. 

 

Curi is a full-service advisory firm that serves physicians and their practices. Their valued advice is grounded in your priorities and elevated in your outcomes. They are driven by a deep understanding of your specific circumstances in medicine, business, and life. To read a few important points to keep in mind about the program, including discounts, administrative defense, cyber coverage, aggressive claims handling, and complimentary risk management CME activities, visit our website.



IMPORTANT UPDATE

SPRINT no longer classified as PNT 



SPR is happy to announce an important update regarding Humana Medicare Advantage. As of May 1, Humana is now recognizing SPRINT as a PNS therapy. Previously, SPRINT was categorized as PNT (Percutaneous Nerve Stimulation), which allowed denials on the grounds that the therapy fell outside the NCD.


Additional details are as follows:

Payer: Humana Medicare Advantage (click here to view policy)

Policy Title: Peripheral Nerve Stimulators

Policy changes: SPRINT no longer misclassified as PNT and is now appropriately classified as PNS. Humana is applying the Noridian Medicare LCD criteria to ALL PNS devices – Including SPRINT PNS!

Effective Date: 5/1/2025


Click here to view a PDF of the official policy update.

 

Group Purchasing Organization Offer Better Pricing and Creates Added Value


ASIPP has formed a partnership with Henry Schein and PedsPal, a national GPO that has a successful history of negotiating better prices on medical supplies and creating value-added services for independent physicians. Working with MedAssets, PedsPal provides excellent pricing on products like contrast media that alleviate some of the financial pressures you experience today.



Learn More


For updated information concerning tariffs on products, click here.

 
 

ASIPP, Fedora Healthcare Solutions Partnership


ASIPP offers our members the benefit of a unique revenue cycle management/ billing service.



We have received a tremendous amount of interest in the ASIPP billing and coding program.




Click here to learn more about the negotiated rate for practices and more!

Like and Follow ASIPP® on Facebook, X, LinkedIn,

and YouTube for the most up-to-date news

related to you, your practice, and your patients!